Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer | PBYI Stock News
Puma Biotechnology Inc Company Profile - GlobalData
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology falls more than 20%
PumaBiotech (@pumabiotech) / X
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology unveils Phase II breast cancer trial design
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Upgraded by StockNews.com - MarketBeat
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotechnology
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology: Profitable, Troubled, But Worth A Good Look (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
PBYI - Puma Biotechnology, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqGS)
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer | Business Wire
Puma Biotechnology Inc (PBYI) Stock Message Board | InvestorsHub
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?
Puma Biotechnology, Inc.
